Lipocine Inc., a biopharmaceutical company focused on oral delivery of therapeutics, announced that its licensing partner, Verity Pharma, has filed a New Drug Submission (NDS) for TLANDO® in Canada. TLANDO is the first and only oral testosterone replacement therapy $(TRT)$ approved by the U.S. FDA that does not require dose titration. This submission represents a significant step towards making TLANDO available in the Canadian market, which sees over 700,000 TRT prescriptions written annually. If approved, TLANDO could capture a substantial market share due to its unique oral administration and the limited promotional activities for current TRTs. Lipocine and Verity Pharma entered an exclusive licensing agreement in January 2024 for commercial rights in the United States and Canada.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.